ORFV: A Novel Oncolytic and Immune Stimulating Parapoxvirus Therapeutic
Julia L. Rintoul(University of Ottawa), John C. Bell(Ottawa Hospital), Harold Atkins(University of Ottawa), Manijeh Daneshmand(University of Ottawa), Rebecca C. Auer(Ottawa Hospital), Byram W. Bridle(PhytoCeutica (United States)), Christiano Tanese de Souza(Ottawa Hospital), Chantal G. Lemay(University of Ottawa), Yonghong Wan(McMaster University Medical Centre), Pamela S. Ohashi(University Health Network), Andrew A. Mercer(Health Research Council of New Zealand), Marianne M. Stanford, Theresa Falls(Ottawa Hospital), Brian D. Lichty(McMaster University Medical Centre), Lee‐Hwa Tai(Université de Sherbrooke)
Cited by 71
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803